Latest Options Offer News

ClearVue Technologies is inviting eligible shareholders to participate in a $1 million Share Purchase Plan at a discount, following a $5 million institutional placement. The capital raised will support ERP rollout, R&D, and working capital.

1414 Degrees offers bonus Loyalty Options to shareholders alongside a $8.45 million capital raise aimed at advancing its clean energy projects, including the Aurora Energy Precinct and SiNTL commercialisation.

Centuria Capital Group has launched the retail component of its $100 million entitlement offer, aiming to raise approximately $35 million. The equity raising supports expansion in AI infrastructure and real estate funds management.

Australian Oil Company Limited has closed its Share Purchase Plan, raising $155,000 by issuing over 54 million shares at $0.0029 each, to support ongoing exploration in Queensland’s Surat Basin.

ClearVue Technologies has secured A$6 million through a $5 million institutional placement and a fully underwritten $1 million Share Purchase Plan, aiming to bolster its balance sheet and fund international expansion and product development.

Buru Energy has launched a prospectus offering over 207 million new options free-attaching to a recent $5.3 million placement, aiming to back the commercialisation of its Rafael Gas Project and bolster working capital.

Microba Life Sciences is targeting a $6 million capital raise through a $1 million Securities Purchase Plan and a $5 million Placement, both subject to shareholder approval. The funds aim to accelerate diagnostics growth and develop a new testing product.

Thrive Tribe Technologies (ASX:1TT) is issuing up to 1.5 billion free attaching options to recent placement participants, exercisable at $0.003 and expiring in 2029, potentially raising $4.5 million if fully exercised.

Bounty Oil & Gas NL has issued a prospectus offering over 632 million new options to eligible investors as part of a broader recapitalisation, potentially raising $6.3 million if exercised.

Racura Oncology has secured $31.2 million in funding to advance its lead cancer drug RC220, including a strategic $1 million private placement to a specialist healthcare investor.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Ovanti Limited is proposing to issue over 520 million free-attaching options to recent placement investors and its lead manager, exercisable at $0.025 and expiring in 2030, pending shareholder approval.